Early guidelines suggested initiating ART at two weeks of anti-TB treatment for individuals with CD4 less than 200 cells/mm3 and eight weeks for those with CD4 between 200 and 350 cells/mm3. The gene discussed is CD4; the disease is tuberculosis.